Interleukin 10 and transforming growth factor-beta 1 plasma levels in atopic dogs before and during immunotherapy.
Journal
The Veterinary record
ISSN: 2042-7670
Titre abrégé: Vet Rec
Pays: England
ID NLM: 0031164
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
28
10
2021
received:
21
08
2020
accepted:
28
11
2021
pubmed:
24
12
2021
medline:
22
6
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
Human studies suggest that the cytokines, interleukin 10 (IL-10) and transforming growth factor-beta 1 (TGF-ß1) may play an important role in allergen-specific immunotherapy (ASIT). However, there is little known about the function of these cytokines in atopic dogs. This study compared the plasma levels of IL-10 and TGF-ß1 in atopic and control dogs and investigated their changes during different ASIT approaches. A total of 54 atopic and 32 control dogs were included. Immunotherapy was performed in 30 atopic dogs. The dogs undergoing immunotherapy were allocated to four groups of different ASIT approaches (namely subcutaneous, intralymphatic, sublingual ASIT and subcutaneous ASIT with recombinant allergens). Blood samples were collected at four timepoints throughout the one year of ASIT. Canine atopic dermatitis extent and severity index, pruritus visual analogue scale and medication score were recorded at each timepoint. Commercially available ELISA kits were used to quantify IL-10 and TGF-ß1 in plasma. There was no significant difference in IL-10 and TGF-ß1 between atopic and control dogs. The IL-10 levels were significantly increased in the intralymphatic group at the end of the study. No significant differences were found in the other groups for both IL-10 and TGF-ß1. The findings of this work suggest that IL-10 and TGF-ß1 cannot be used to monitor the course of the disease during ASIT.
Sections du résumé
BACKGROUND
Human studies suggest that the cytokines, interleukin 10 (IL-10) and transforming growth factor-beta 1 (TGF-ß1) may play an important role in allergen-specific immunotherapy (ASIT). However, there is little known about the function of these cytokines in atopic dogs. This study compared the plasma levels of IL-10 and TGF-ß1 in atopic and control dogs and investigated their changes during different ASIT approaches.
METHODS
A total of 54 atopic and 32 control dogs were included. Immunotherapy was performed in 30 atopic dogs. The dogs undergoing immunotherapy were allocated to four groups of different ASIT approaches (namely subcutaneous, intralymphatic, sublingual ASIT and subcutaneous ASIT with recombinant allergens). Blood samples were collected at four timepoints throughout the one year of ASIT. Canine atopic dermatitis extent and severity index, pruritus visual analogue scale and medication score were recorded at each timepoint. Commercially available ELISA kits were used to quantify IL-10 and TGF-ß1 in plasma.
RESULTS
There was no significant difference in IL-10 and TGF-ß1 between atopic and control dogs. The IL-10 levels were significantly increased in the intralymphatic group at the end of the study. No significant differences were found in the other groups for both IL-10 and TGF-ß1.
CONCLUSION
The findings of this work suggest that IL-10 and TGF-ß1 cannot be used to monitor the course of the disease during ASIT.
Substances chimiques
Allergens
0
Immunologic Factors
0
Interleukin-10
130068-27-8
Transforming Growth Factors
76057-06-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1270Informations de copyright
© 2021 The Authors. Veterinary Record published by John Wiley & Sons Ltd on behalf of British Veterinary Association.
Références
Nuttall T, Uri M, Halliwell R. Canine atopic dermatitis-what have we learned? Vet Rec. 2013;172:201-7.
Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol. 2006;114:207-8.
Pucheu-Haston CM, Bizikova P, Marsella R, Santoro D, Nuttall T, Eisenschenk MNC. Review: lymphocytes, cytokines, chemokines and the T-helper 1-T-helper 2 balance in canine atopic dermatitis. Vet Dermatol. 2015;26:124-e32.
Olivry T, Deboer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis: guidelines for canine atopic dermatitis. Vet Dermatol. 2010;21:233-48.
Griffin. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol. 2001;81(3-4):363-83
Willemse A, Van den Brom WE, Rijnberk A. Effect of hyposensitization on atopic dermatitis in dogs. J Am Vet Med Assoc. 1984;184:1277-80.
Fischer NM, Rostaher A, Favrot C. A comparative study of subcutaneous, intralymphatic and sublingual immunotherapy for the long-term control of dogs with nonseasonal atopic dermatitis. Vet Dermatol. 2020;31:365-e96.
Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205-14.
Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761-71.
Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006;117:433-42.
Ahmadiafshar A, Taymourzadeh B. Evaluation of IL10, TGF-B and Specific IgE and IgG Levels during sublingual rye grass immunotherapy. J Allergy Ther. 2013;4(2):132. https://doi.org/10.4172/2155-6121.1000132.
Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol. 2007;120:707-13.
Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, et al. Sublingual immunotherapy with dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy. 2006;36:261-72.
Liu W, Zeng Q, Luo R. Predictors for short-term efficacy of allergen-specific sublingual immunotherapy in children with allergic rhinitis. Mediators Inflamm. 2020;2020:1847061.
Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172:3252-9.
Hauck V, Hügli P, Meli ML, Rostaher A, Fischer N, Hofmann-Lehmann R, et al. Increased numbers of FoxP3-expressing CD4 + CD25 + regulatory T cells in peripheral blood from dogs with atopic dermatitis and its correlation with disease severity. Vet Dermatol. 2016;27:26-e9.
Beccati M, Martini V, Comazzi S, Fanton N, Cornegliani L. Lymphocyte subpopulations and Treg cells in dogs with atopic dermatitis receiving ciclosporin therapy: a prospective study. Vet Dermatol. 2016;27:17-e5.
Rostaher A, Fischer NM, Urwyler A, Favrot C. Circulating CD4(+)CD25(+)Foxp3(+) T regulatory cell levels in an experimental model of canine atopic dermatitis. Vet Dermatol. 2018;29:511-e171.
Keppel KE, Campbell KL, Zuckermann FA, Greeley EA, Schaeffer DJ, Husmann RJ. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy. Vet Immunol Immunopathol. 2008;123:337-44.
Marteles D, Verde MT, Conde T, Pereboom D, Casanova Á, Villanueva-Saz S, et al. Effects of allergen-specific immunotherapy on peripheral blood regulatory T cells and serum concentrations of cytokines and immunoglobulins in horses with allergic dermatitis. Int Immunopharmacol. 2019;74:105674.
Attias M, Al-Aubodah T, Piccirillo CA. Mechanisms of human FoxP3 + T reg cell development and function in health and disease. Clin Exp Immunol. 2019;197:36-51 cei.13290.
Pinheiro D, Singh Y, Grant CR, Appleton RC, Sacchini F, Walker KRL, et al. Phenotypic and functional characterization of a CD4+ CD25high FOXP3high regulatory T-cell population in the dog: CD4+ regulatory T cells in the dog. Immunology 2011;132:111-22.
Knueppel A, Lange S, Sekora A, Altmann S, Freund M, Junghanss C. Phenotypic and functional characterization of freshly isolated and expanded canine regulatory T cells. Exp Anim. 2011;60(5):471-9.
Garden OA, Pinheiro D, Cunningham F. All creatures great and small: regulatory T cells in mice, humans, dogs and other domestic animal species. Int Immunopharmacol. 2011;11:576-88.
Vadasz Z, Haj T, Toubi E. The Role of B regulatory cells and Semaphorin3A in atopic diseases. Int Arch Allergy Immunol. 2014;163:245-51.
Saraiva M, O'garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170-81.
Koury J, Ramirez A, Xie C, Harb J, Dong C, Maki C, et al. Phosphodiesterase 4D, miR-203 and selected cytokines in the peripheral blood are associated with canine atopic dermatitis. PLOS One. 2019;14:e0218670.
Majewska A, Gajewska M, Dembele K, Maciejewski H, Prostek A, Jank M. Lymphocytic, cytokine and transcriptomic profiles in peripheral blood of dogs with atopic dermatitis. BMC Vet Res. 2016;12:174.
Schlotter YM, Rutten VPMG, Riemers FM, Knol EF, Willemse T. Lesional skin in atopic dogs shows a mixed Type-1 and Type-2 immune responsiveness. Vet Immunol Immunopathol. 2011;143:20-6.
Maina E, Devriendt B, Cox E. Changes in cytokine profiles following treatment with food allergen-specific sublingual immunotherapy in dogs with adverse food reactions. Vet Dermatol. 2017;28:612-e149.
Hayashiya S, Tani K, Morimoto M, Hayashi T, Hayasaki M, Nomura T, et al. Expression of T-helper 1 and T-helper 2 cytokine mRNAs in freshly isolated peripheral blood mononuclear cells from dogs with atopic dermatitis. J Vet Med Ser A. 2002;49:27-31.
Vitger AD, Stallknecht BM, Miles JE, Hansen SL, Vegge A, Bjørnvad CR. Immunometabolic parameters in overweight dogs during weight loss with or without an exercise program. Domest Anim Endocrinol. 2017;59:58-66.
Mizuno T, Kamiyama H, Mizuno M, Mizukoshi T, Shinoda A, Harada K, et al. Plasma cytokine levels in dogs undergoing cardiopulmonary bypass. Res Vet Sci. 2015;101:99-105.
Van De Velde H, Janssens GPJ, Rochus K, Duchateau L, Scharek-Tedin L, Zentek J, et al. Proliferation capacity of T-lymphocytes is affected transiently after a long-term weight gain in Beagle dogs. Vet Immunol Immunopathol. 2013;152:237-44.
Nuttall TJ, Knight PA, McAleese SM, Lamb JR, Hill PB. Expression of Th1, Th2 and immunosuppressive cytokine gene transcripts in canine atopic dermatitis. Clin Exp Allergy. 2002;32:789-95.
Fischer N, Rostaher A, Favrot C. Intralymphatic immunotherapy: an effective and safe alternative route for canine atopic dermatitis. Schweiz Arch Tierheilkd. 2016;158:646-52.
Favrot C, Steffan J, Seewald W, Picco F. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol. 2010;21:23-31.
Fischer N, Tarpataki N, Leidi F, Rostaher A, Favrot C. An open study on the efficacy of a recombinant Derf 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland. Vet Dermatol. 2018;29:337-e118.
Rybníček J, Lau-Gillard PJ, Harvey R, Hill PB. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol. 2009;20:115-22.
Mueller RS, Fieseler KV, Fettman MJ, Zabel S, Rosychuk RAW, Ogilvie GK, et al. Effect of omega-3 fatty acids on canine atopic dermatitis. J Small Anim Pract. 2004;45:293-7.
Olivry T, Saridomichelakis M, Nuttall T, Bensignor E, Griffin CE, Hill PB. Validation of the canine atopic dermatitis extent and severity index (CADESI)-4: a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs. Vet Dermatol. 2014;25:77-e25.
Prete GD, Carli MD, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S, et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 1993;9:150353-360.
Quaranta A, Siniscalchi M, Frate A, Iacoviello R, Buonavoglia C, Vallortigara G. Lateralised behaviour and immune response in dogs: relations between paw preference and interferon-γ, interleukin-10 and IgG antibodies production. Behav Brain Res. 2006;166:236-40.
Felix AOC, Guiot EG, Stein M, Felix SR, Silva EF, Nobre MO. Comparison of systemic interleukin 10 concentrations in healthy dogs and those suffering from recurring and first time Demodex canis infestations. Vet Parasitol. 2013;193:312-5.
Analytical Methods Committee. AMC technical brief - what should be done with values below detection limits? London: Royal Society of Chemistry; 2001. Mentioning the unmentionable.
Hussein PY, Zahran F, Wahba AA, Ahmad AS, Ibrahiem MM, Shalaby SM, et al. Interleukin 10 receptor alpha subunit (IL-10RA) gene polymorphism and IL-10 serum levels in Egyptian atopic patients. J Investig Allergol Clin Immunol. 2010;20:7.
Shachar I, Karin N. The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol. 2013;93:51-61.
Krafft E, Lybaert P, Roels E, Laurila HP, Rajamäki MM, Farnir F, et al. Transforming growth factor Beta 1 activation, storage, and signaling pathways in idiopathic pulmonary fibrosis in dogs. J Vet Intern Med. 2014;28:1666-75.
Shida M, Kadoya M, Park S-J, Nishifuji K, Momoi Y, Iwasaki T. Allergen-specific immunotherapy induces Th1 shift in dogs with atopic dermatitis. Vet Immunol Immunopathol. 2004;102:19-31.
Mueller RS. Update on allergen immunotherapy. Vet Clin North Am Small Anim Pract. 2019;49:1-7.
Scott DW. Observations on canine atopy. J Am Anim Hosp Assoc. 1981;17:91-100.
Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998;102:98-106.
Jensen-Jarolim E, Bachmann MF, Bonini S, Jacobsen L, Jutel M, Klimek L, et al. State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020;75:746-60.
Declue AE, Sharp CR, Harmon M. Plasma inflammatory mediator concentrations at ICU admission in dogs with naturally developing sepsis. J Vet Intern Med. 2012;26:624-30.
Fung HL, Calzada J, Saldaña A, Santamaria AM, Pineda V, Gonzalez K, et al. Domestic dog health worsens with socio-economic deprivation of their home communities. Acta Trop. 2014;135:67-74.
Kjelgaard-Hansen M, Luntang-Jensen M, Willesen J, Jensen AL. Measurement of serum interleukin-10 in the dog. Vet J. 2007;173:361-5.
Lee SH, Ra JC, Oh HJu, Kim MJ, Setyawan EMN, Choi YB, et al. Clinical assessment of intravenous endothelial progenitor cell transplantation in dogs. Cell Transplant. 2019;28:943-54.